Why the study?
Primary cardiac intimal sarcoma is a rare entity with a poor prognosis that often requires distinction from other undifferentiated cardiac sarcomas.
Case Report (n=1)
No
This case highlights the diagnostic utility of MDM2 and CDK4 amplification for identifying primary cardiac intimal sarcoma, an aggressive malignancy requiring early multidisciplinary intervention.
Supports MDM2/CDK4 testing to guide multidisciplinary care in cardiac intimal sarcoma; hypothesis-generating for anlotinib integration in this rare tumor.
Aim: Primary cardiac intimal sarcoma is a rare entity with a poor prognosis, often requiring distinction from other undifferentiated cardiac sarcomas. Case Presentation: A 55-year-old female presented with symptoms of heart failure. Imaging identified dual left atrial masses compromising mitral inflow and pulmonary venous return. Surgical excision was performed, and morphological analysis revealed a high-grade spindle cell sarcoma. Crucially, the diagnostic dilemma was resolved through molecular testing; immunohistochemistry showed diffuse overexpression of MDM2 and CDK4, and fluorescence in situ hybridization (FISH) confirmed the amplification of the MDM2 and CDK4 loci. Conclusion: This case illustrates the diagnostic utility of MDM2 and CDK4 as specific biomarkers for cardiac intimal sarcoma. It reinforces the necessity of a multidisciplinary approach involving advanced molecular pathology to ensure accurate classification and appropriate management of rare cardiac malignancies.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) conducted a case report in Primary cardiac intimal sarcoma (n=1). Surgical resection, adjuvant chemotherapy, and anlotinib was evaluated on Overall survival.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: